Medline Posts $7.86B in Third-Quarter Sales
MDLN is trading near its 52-week low of $31.37 (9.1% above the low).
Summary
Medline reported third-quarter sales of $7.86B, the first top-line figure for the period, with third-quarter EPS of 22c. The company raised its 2026 organic sales guidance to 10%-10.5% from 9%-10% and backed 2026 adjusted EBITDA guidance of $3.3B-$3.4B. The results land against a rough stretch: shares fell 13% in early October after the company disclosed product quality issues and a securities fraud investigation opened, and the FDA warned on Medline-branded beds on October 29 after two deaths and 16 injuries were reported. The company is also exiting all Medline Brand beds following a voluntary field action, with estimated costs of up to a disclosed amount in the October 21 8-K. Sales alone don't settle the margin question — the bed exit costs and any quality-related charges will show up below the top line.
At the time of this announcement, MDLN was trading at $34.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.8B. The 52-week trading range was $31.37 to $50.88. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.